PittPharmacy Associate Professor Jan Beumer, PharmD, PhD, DABT was elected co-chair of The National Cancer Institute Investigational Drug Steering Committee Phase 1 Program.
The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) provides NCI with broad external scientific and clinical input on the design and prioritization of phase I and phase II trials with agents for which Cancer Therapy Evaluation Program (CTEP) holds an Investigational New Drug (IND) application.
The IDSC aims to increase the predictive value of early phase trials, resulting in the design of more successful phase III trials.
